



Implementation of a liquidity contract

Stallergènes has entrusted SG Securities Paris with the implementation of a liquidity contract complying with the AFEI Ethics Charter of 14 March 2005, approved by the AMF's decision of 22 March 2005, in relation to shares in Stallergènes, through a contract effective from today's date for a period of one year, renewable by tacit agreement.

The following resources were allocated to the liquidity account for the implementation of the contract:

- € 1,500,000 (one million five hundred thousand euro),
- 30,000 (thirty thousand) treasury shares.

The objective of the implementation of this contract is to improve share liquidity and reduce share price volatility.

About STALLERGENES

STALLERGENES is a biopharmaceutical company specialised in desensitisation treatments for allergy-related respiratory diseases such as allergic rhino-conjunctivitis, allergic rhinitis, and allergic asthma.

A pioneer and leader in sublingual desensitisation treatments, STALLERGENES devotes 18% of its turnover to Research and Development, and in particular development of a new therapeutic class, namely sublingual desensitisation treatment in tablet form.

In 2006, STALLERGENES recorded a turnover of 126.5 million euros, half of which on markets outside France.

STALLERGENES shares are listed on Euronext, Compartment B of the Euronext Paris Stock Exchange
Codes: ISIN FR0000065674, Reuters GEN.PA, Bloomberg GEN.FP

Additional information on STALLERGENES is available at: www.stallergenes.com



Your contacts

PAVIE FINANCE

Albert SAPORTA - Chairman

Lucile de FRAGUIER

Christian THIRY - Chief Financial Officer

Analyst-investor Relations

Tel: +33 (0)1 55 59 20 95

Tel: +33 (0)1 42 15 04 39

investorrelations@stallergenes.fr

contact@pavie-finance.com